Giordano SH (2003) Update on locally advanced breast cancer. Oncologist 8:521–530. https://doi.org/10.1634/theoncologist.8-6-521

Article  PubMed  Google Scholar 

Rustogi A, Budrukkar A, Dinshaw K, Jalali R (2005) Management of locally advanced breast cancer: evolution and current practice. J Can Res Ther 1:21–30. https://doi.org/10.4103/0973-1482.16086

Article  Google Scholar 

Thompson AM, Moulder-Thompson SL (2012) Neoadjuvant treatment of breast cancer. Ann Oncol 23:231–236. https://doi.org/10.1093/annonc/mds324

Article  Google Scholar 

Dani M, McDonnell J, Karp S, Jaffe V (2007) Do breast cancer tumours downsize as well as downgrade with neoadjuvant chemotherapy? Breast Cancer Res 9:SP3. https://doi.org/10.1186/bcr1709

Article  Google Scholar 

Corben AD, Abi-Raad R, Popa I, Chy T, Macklin EA, Koerner FC, Taghian AG, Brachtel EF (2013) Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy. A comparison between classifications and their practical application. Arch Pathol Lab Med 137:1074–1082. https://doi.org/10.5858/arpa.2012-0290-OA

Article  PubMed  Google Scholar 

Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L (2012) Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 19:1508–1516. https://doi.org/10.1245/s10434-011-2108-2

Article  PubMed  Google Scholar 

Philipovskiy A, Corral J, Dwivedi KA, Heydarian R, Gaur S (2019) Efficacy of neoadjuvant versus adjuvant chemotherapy in Hispanic/Latino (H/L) women with local or locally advanced triple-negative breast cancer (TNBC). In Vivo 33:1227–1234. https://doi.org/10.21873/invivo.11594

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ, Panel Members (2015) Tailoring therapies – improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol 26:1533–1546. https://doi.org/10.1093/annonc/mdv221

Article  CAS  PubMed  PubMed Central  Google Scholar 

Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F, Guidelines Committee ESMO (2015) Primary breast cancer: ESMO clinical practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:8–30. https://doi.org/10.1093/annonc/mdv298

Article  Google Scholar 

Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF (2015) Residual disease characterization working Group of the Breast International Group-North American Breast Cancer Group Collaboration. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol 28:1185–1201. https://doi.org/10.1038/modpathol.2015.74

Article  PubMed  Google Scholar 

Cserni G, Kulka J, Francz M, Járay B, Kálmán E, Kovács I, Krenács T, Udvarhelyi N, Vass L (2016) Pathological diagnosis, work-up and reporting of breast cancer. Recommendations of the 3rd Hungarian consensus conference on breast Cancer. Magy Onkol 60:209–228

PubMed  Google Scholar 

von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796–1804. https://doi.org/10.1200/JCO.2011.38.8595

Article  Google Scholar 

U.S. Food and Drug Administration (2014) Guidance for Industry: Pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM305501.pdf Accessed 19 Jan 2020

Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierly JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Madera M, Asare EA (2017) AJCC Cancer staging manual, 8th edn. Springer, Chicago

Book  Google Scholar 

Sethi D, Sen R, Parshad S, Khetarpal S, Garg M, Sen J (2012) Histopathologic changes following neoadjuvant chemotherapy in various malignancies. Int J Appl Basic Med Res 2:111–116. https://doi.org/10.4103/2229-516X.106353

Article  PubMed  PubMed Central  Google Scholar 

Park CK, Jung WH, Koo JS (2016) Pathologic evaluation of breast cancer after neoadjuvant therapy. J Pathol Transl Med 50:173–180. https://doi.org/10.4132/jptm.2016.02.02

Article  PubMed  PubMed Central  Google Scholar 

Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, Taghian A, Wickerham DL, Wolmark N (2012) Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and bowel project B-18 and B-27. J Clin Oncol 30:3960–3966. https://doi.org/10.1200/JCO.2011.40.8369

Article  PubMed  PubMed Central  Google Scholar 

Chevallier B, Chollet P, Merrouche Y, Roche H, Fumoleau P, Kerbrat P, Genot JY, Fargeot P, Olivier JP, Fizames C et al (1995) Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 13:1564–1571. https://doi.org/10.1200/JCO.1995.13.7.1564

Article  CAS  PubMed  Google Scholar 

Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180:297–306

CAS  PubMed  Google Scholar 

Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12:320–327. https://doi.org/10.1016/s0960-9776(03)00106-1

Denkert C, Schickling O, von Minckwitz G (2006) Preoperative chemotherapy in breast cancer and the development of new predictive markers. Verh Dtsch Ges Pathol 90:114–123

CAS  PubMed  Google Scholar 

Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 28:4414–4422. 10.1200/JCO.2007.10.6823

Wells CA, Amendoeira I, Bellocq JP, Bianchi S, Boecker W, Borisch B, Rasmussen B, Callagy GM, Chmielik E, Cordoba A, Cserni G, Decker T, DeGaetano J, Drijkoningen M, Ellis IO, Faverly DR, Foschini MP, Frković-Grazio S, Grabau D, Heikkilä P, Iacovou E, Jacquemier J, Kaya H, Kulka J, Lacerda M, Liepniece-Karele I, Martinez-Penuela J, Quinn CM, Rank F, Regitnig P, Reiner A, Sapino A, Tot T, Van Diest P, Varga Z, Wesseling J, Zolota V, Zozaya-Alvarez E (2013) S2: pathology update. Quality assurance guidelines for pathology. In: European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition, Supplements. Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (eds.). European Commission, Office for Official Publications of the European Union, Luxembourg, pp. 73–120

Chollet P, Abrial C, Durando X, Thivat E, Tacca O, Mouret-Reynier MA, Leheurteur M, Kwiatkowski F, Dauplat J, Penault-Llorca F (2008) A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN). Cancer J 14:128–132. https://doi.org/10.1097/PPO.0b013e31816bdea2

Article  PubMed  Google Scholar 

Fowler AM, Mankoff DA, Joe BN (2017) Imaging neoadjuvant therapy response in breast cancer. Radiology 285:358-375. https://doi.org/10.1148/radiol.2017170180, 285, 358, 375

Royal College of Pathologists of Australasia (2012) Invasive breast cancer structured reporting protocol. https://www.rcpa.edu.au/getattachment/7b70b3e5-5dca-403f-893e-638815f487b1/Protocol-invasive-breast-cancer.aspx. Accessed 22 Nov 2019

Lambein K, Van de Vijver K, Faverly D, Colpaert C (2011) Belgian guidelines for laboratory handling and pathology reporting of breast carcinoma after neoadjuvant therapy. Belg J Clin Oncol 5:144–153. https://doi.org/10.1111/j.1365-2559.2006.02419.x

Article  Google Scholar 

Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe (2018) Diagnosis and treatment of patients with primary and metastatic breast cancer. https://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/2018-03/EN/Gesamt_PDF_Englisch/Updated_Guidelines_2018.pdf.

NHS Cancer Screening Programmes jointly with The Royal College of Pathologists (2005) Pathology reporting of breast disease. https://www.cmcanceralliance.nhs.uk/application/files/3615/4815/5660/Guidelines_for_NHSBSP58_January_2005_Reviewed_CNG_June_2010.pdf Accessed 18 Jan 2020

Integraal Kankercentrum Nederland (2012) Beoordeling na neoadjuvante chemo- of endocriene therapie. http://www.oncoline.nl/breastcancer Accessed 26 June 2018

Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Hill KA, Kleer C, O’Malley FP, Page DL, Smith BL, Tan LK, Weaver DL, Winer E, Simpson JF (2012) Protocol for the examination of specimens from patients with invasive carcinoma of the breast. http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/cp-breast-invasive-16protocol-3300.pdf Accessed 22 Nov 2019

Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN (2017) Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol 35:1049–1060. https://doi.org/10.1200/JCO.2015.63.1010

Article  CAS  PubMed  PubMed Central  Google Scholar